Mark Yarchoan Highlights Study on Timing of ICI for Improved NSCLC Outcomes
Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared a post on X about recent article by Yongchang Zhangand colleagues:
“I doubted studies claiming ICI infusion timing mattered (ICI half-life = weeks!). Afternoon patients surely differ in unmeasurable ways. But now a randomized trial morning ICI does better…
Here is the randomized study of time of day ICI infusion and outcomes.”
Title: Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.
Authors: Yongchang Zhang, Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, Huan Yan, Wenjuan Jiang, Jiacheng Dai, Nachuan Zou, Shidong Xu, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Xiaomei Li, Boris Duchemann, Guoqiang Chen, Christoph Scheiermann, Nong Yang, and Francis Albert Lévi
More posts featuring Mark Yarchoan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023